Skip to content

Sensorimotor Mapping in Patients With Writer's Cramp

Corticomotor Plasticity as a Biomarker for Functional Improvement After Botulinium Treatment in Writer's Cramp

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03085745
Acronym
IWCToxin
Enrollment
15
Registered
2017-03-21
Start date
2017-02-20
Completion date
2019-05-19
Last updated
2018-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Writer's Cramp

Keywords

Writer's cramp, Sensorimotor plasticity, TMS, Afferent inhibition, Motor mapping, Sensory mapping, adaptive sensorimotor synergies, fine motor control

Brief summary

Writer's cramp (WC) is a form of focal dystonia, a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements, postures, or both. It typically manifests while writing, making handwriting impossible in the most severe cases. Treatment can be difficult, but one effective and well-tolerated treatment consists in local muscle injections with botulinum toxin. Although clinical improvement seems to be related to focal muscle chemodenervation, central plasticity changes may occur. The main aim of the study is to characterize and quantify the changes in intrinsic hand muscle cortical representations at rest and during isometric contractions of the finger muscles before and after treatment with botulinum toxin and the changes in sensorimotor integration in patients with writer's cramp.

Detailed description

Fifteen WC patients will be enrolled in the study. A newly developed neuronavigated and robotized Transcranial Magnetic Stimulation (TMS) mapping approach will be used. It will generate a linear mediolateral excitability profile for two intrinsic hand muscle based on the mean Motor Evoked Potentials (MEPs) amplitude at each stimulation site. Changes in excitability profiles will reflect spatial reorganization of cortical motor output maps of the hand muscles. To measure afferent inhibition, the same mapping procedure will be repeated with a brief peripheral electrical stimulation prior the TMS pulse. These Short Afferent Inhibition (SAI) profiles will reflect the influence of the primary sensory cortex over the motor cortex. Finally, the stimulation grid will be translated to the primary somatosensory cortex and a paired pulse TMS paradigm will be applied just after a digital nerve stimulation. It will generate afferent signal processing profiles based on subjective perception for the index finger and the little finger. Participants will be tested before the botulinum toxin injections and at three different time points after the injections (7 days, 1 month and 3 months after). Botulinum toxin injections will be performed using ultrasound guide together with electromyography/nerve stimulation into the clinical affected hand muscles. Muscle selection for injections will be based on clinical criteria of postural deviation of the hand and fingers and responsible muscle forces. The dose will be chosen according to published clinical recommendation concerning starting dose for WC after the clinical examination, usually between 5 and 10 units of Xeomin® both for flexor and extensor hand/forearm muscles. To precisely assess treatment efficacy, the Writer's Cramp Rating Scale (WCRS) as well as computer-based hand writing analyses and standard sensorimotor tests of hand functions (the Nine Holes Peg Test, a tapping test and a tactile spatial acuity task) will be performed before the injections and at each follow up session.

Interventions

OTHERTranscranial Magnetic Stimulation (TMS)

TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Suffering from a writer's cramp * aged 30-80 years old * Botulinum toxin injection performed in clinical routine for their disease * Affiliated to a social security system * Sufficient intellectual capacities to understand the tasks to perform * Written consent obtained

Exclusion criteria

* Impossibility to remain sitting down without pain or discomfort for at least 3 consecutive hours * History or psychiatric or neurological disease, different from dystonia. * Subject under judicial oversight * Subject being within exclusion period * Subject not reachable in case of emergency, * Presence of one or several contraindications to TMS * Subject covered by the following articles from the french Code de la Santé Publique: L1121-5, L1121-6, L1121-7 et L1121-8.

Design outcomes

Primary

MeasureTime frameDescription
Corticospinal excitability profiles of intrinsic hand musclesThis measure will be performed before the injection of botulinum toxin and 7 days after, 30 days after and 3 months after the injection.We will use a newly developed neuronavigated and robotized Transcranial Magnetic Stimulation (TMS) mapping approach consisting in an individually adjusted stimulation grid located along the longitudinal axis of the motor cortex. It will generate a linear mediolateral excitability profile for each hand muscle based on the mean Motor Evoked Potentials (MEPs) amplitude at each stimulation site, on both hemispheres. Changes in excitability profiles will reflect spatial reorganization of cortical motor output maps of the hand muscles.

Countries

France

Contacts

Primary ContactEstelle Raffin
estelle.raffin@univ-grenoble-alpes.fr456520688
Backup Contactanais adolle
aadolle@chu-grenoble.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026